Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersEditorials
You have accessRestricted Access

Improving Equity in Medication Use through Better Kidney Function Measurement

Delphine S. Tuot
JASN August 2020, 31 (8) 1657-1658; DOI: https://doi.org/10.1681/ASN.2020060880
Delphine S. Tuot
Division of Nephrology, University of California, San Francisco, San Francisco, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • disparities
  • diabetes
  • eGFR
  • metformin

Racial/ethnic and sex disparities with respect to diabetes prevalence and health outcomes are profound and well recognized. Nationally representative data suggest the prevalence of diagnosed and undiagnosed diabetes among adults in the United States is 38% higher among non-Hispanic Blacks (16.4%; 95% CI, 14.7 to 18.2), 27% higher among non-Hispanic Asians (14.9%; 95% CI, 12.0 to 18.2) and 24% higher among Hispanics (14.7%; 95% CI, 12.5 to 17.3) compared with non-Hispanic Whites (11.9%; 95% CI, 10.9 to 13.0).1 Additionally, Black and Hispanic patients have been demonstrated to shoulder a greater burden of diabetes complications, such as ESKD, retinopathy, neuropathy, and lower extremity amputations.2 Diabetes prevalence is similar between the sexes (among men, 14.0%; 95% CI, 12.3 to 15.5; among women, 12.0%; 95% CI, 11.0 to 13.2), but women with diabetes have excess risk of macrovascular complications including stroke and coronary heart disease.3

Recent data have not demonstrated substantial differences in diabetes quality of care measures, such as frequent glycosylated hemoglobin testing, yearly foot and dilated eye exams, nephropathy testing, and influenza vaccinations, by race/ethnicity among adults, but have identified some differences by sex.3,4 Public health interventions that increase access to and use of routine care, such as Medicaid expansion, may thus have the greatest effect on reducing racial (not sex) disparities over time.5 However, differences in diabetes treatment strategies to attain glycemic control may be another understudied contributor to the poorer health outcomes among racial/ethnic minorities and women with diabetes. Although the number of available oral diabetes medications has proliferated in the past decade, metformin remains the recommended first-line agent for diabetes treatment among individuals with normal renal function as well as those with mild-moderate kidney disease due to its high efficacy and favorable side effect profile.6 Safely expanding metformin use for racial/ethnic minorities and women with diabetes may be a key strategy to diminish existing disparities in health outcomes.

Until recently, the Food and Drug Administration (FDA) recommendations for the prescription of metformin were based on serum creatinine (sCr), a marker of kidney function that is also influenced by a number of determinants that are independent of GFR. Prior research identified race and sex as two variables that may influence creatinine generation; in research cohorts, sCr tended to be higher among self-reported non-Hispanic Black compared with White patients and among men compared with women. Creatinine-based estimating equations for GFR that include coefficients for both of these factors, in addition to age, closely predict measured GFR.7 Thus, leveraging these equations rather than sCr to guide metformin prescription might lessen differences in metformin prescription by race and sex.8

In this issue, Shin et al.9 move beyond conjecture, tangibly demonstrating the effect of clinicians’ use of GFR-estimating equations on metformin prescription.9 The authors identified two 9-month-period prevalent cohorts of adult Black and White patients with diabetes receiving at least one oral hypoglycemic agent who received care from one healthcare system before and after April 8, 2016—the day on which the FDA changed the metformin label to include a contraindication based on eGFR determined by creatinine (eGFRcr; <30 ml/min per 1.73 m2) rather than one based on sCr (>1.4 mg/dl for women or 1.5 mg/dl for men). Black participants in the cohort defined by the 9 months preceding the label change with an eGFR of 30–44 ml/min per 1.73 m2 were 35% less likely to be prescribed metformin compared with their White counterparts (adjusted prevalence ratio [aPR], 0.64; 95% CI, 0.52 to 0.82). In the cohort defined by the 9 months after the label change, this Black-White disparity in metformin prescription was greatly diminished and likely eliminated (aPR, 0.90; 95% CI, 0.74 to 1.09). Metformin prescription for individuals of either race with an eGFR >45 ml/min per 1.73 m2 did not change. During the same time periods, attenuation in sex-based disparities in metformin prescription for individuals with an eGFR of 30–44 ml/min per 1.73 m2 also appeared, although the change was less impressive and nonstatistically significant (aPR before label change, 0.72; 95% CI, 0.58 to 0.88; aPR after label change, 0.79; 95% CI, 0.65 to 0.96). Importantly, these findings were robust to multiple sensitivity analyses and were unique to the prescription of metformin compared with sulfonylureas, which are oral diabetes medications that served as a negative control because their prescribing recommendations did not change during the study time period. Additionally, data from a large healthcare database that included >1 million individuals across 36 different cohorts replicated the results.

The Shin et al. study could not ascertain the exact reasoning behind the rapid change in prescription patterns, nor whether changes were consistent among individual clinicians, which would demonstrate uniform application of the new federal recommendations. However, the findings do strongly suggest the sizable effect that federal agencies have in guiding care delivery. An important next step will be to explore whether changes in metformin prescription patterns are associated with undesirable increases in potential adverse events, namely lactic acidosis, or with the anticipated decreases in racial/sex disparities in diabetes complications.

The FDA metformin label change and the subsequent effect constitute a large step forward toward equity in quality of diabetes care delivery. The label change raises other concerns. eGFRcr is an improvement over sCr alone to guide the prescription of medications that are renally cleared; however, the underlying physiologic mechanisms behind purported racial differences in creatinine generation and clearance are not well understood.7 Application of eGFRcr to guide medication prescription and other clinical decisions based on Black versus non-Black race (a nonbiologic construct) can contribute to racial/ethnic disparities in health outcomes, not only for self-identified Black adults but also for other non-Black, non-White populations. Incorporation of race into clinical algorithms is a subject of increasing debate within the medical community, including but not limited to nephrology.10 Cystatin C–based GFR estimation is one alternative to eGFRcr that is not influenced by race, and was previously predicted to expand metformin prescription compared with sCr even more than eGFRcr among adults with diabetes.8 However, there are current pitfalls with widespread use of eGFR based on cystatin C, including lack of a national measurement standard that prevents comparisons across different laboratories and healthcare providers, as well as the relatively high cost.11

More investment is needed to identify a reliable, convenient, and cost-favorable eGFR test that is based solely on underlying biologic mechanisms, rather than on social constructs that can be misinterpreted and misapplied. If federal agencies adopt such a test to set recommendations for clinical decision making, the United States healthcare delivery system will make great strides toward the delivery of personalized medicine that maximizes public health while preventing racial/ethnic disparities in health outcomes. The rapid change in patterns of metformin prescribing after the FDA label change that Shin et al. documents indicates that clinicians are ready to act upon sound, evidence-based guidance. What are we waiting for?

Disclosures

The author has nothing to disclose.

Funding

None.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related article, “The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD,” on pages 1847–1858.

  • Copyright © 2020 by the American Society of Nephrology

References

  1. ↵
    1. Centers for Disease Control and Prevention
    : National Diabetes Statistics Report, Atlanta, GA, Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services, 2020
  2. ↵
    1. Spanakis EK,
    2. Golden SH
    : Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep 13: 814–823, 2013 pmid:24037313
    OpenUrlCrossRefPubMed
  3. ↵
    1. Woodward M,
    2. Peters SA,
    3. Huxley RR
    : Diabetes and the female disadvantage. Womens Health (Lond) 11: 833–839, 2015 pmid:26368038
    OpenUrlCrossRefPubMed
  4. ↵
    1. Hu R,
    2. Shi L,
    3. Liang H,
    4. Haile GP,
    5. Lee DC
    : Racial/ethnic disparities in primary care quality among type 2 diabetes patients, medical expenditure panel survey, 2012. Prev Chronic Dis 13: E100, 2016 pmid:27490365
    OpenUrlPubMed
  5. ↵
    1. Baicker K,
    2. Taubman SL,
    3. Allen HL,
    4. Bernstein M,
    5. Gruber JH,
    6. Newhouse JP, et al.: Oregon Health Study Group
    : The Oregon experiment--effects of Medicaid on clinical outcomes. N Engl J Med 368: 1713–1722, 2013 pmid:23635051
    OpenUrlCrossRefPubMed
  6. ↵
    1. American Diabetes Association
    : 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2020. Diabetes Care 43[Suppl 1]: S98–S110, 2020 pmid:31862752
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Levey AS,
    2. Titan SM,
    3. Powe NR,
    4. Coresh J,
    5. Inker LA
    : Kidney disease, race, and GFR estimation [published online ahead of print May 11, 2020]. Clin J Am Soc Nephrol doi:10.2215/CJN.00690120pmid:32393465
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Tuot DS,
    2. Lin F,
    3. Shlipak MG,
    4. Grubbs V,
    5. Hsu CY,
    6. Yee J, et al.: CDC CKD Surveillance Team
    : Potential impact of prescribing metformin according to eGFR rather than serum creatinine. Diabetes Care 38: 2059–2067, 2015 pmid:26307607
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Shin J-I,
    2. Sang Y,
    3. Chang AR,
    4. Dunning SC,
    5. Coresh J,
    6. Inker LA, et al
    .: The FDA metformin label change and racial and sex disparities in metformin prescription among patients with CKD. J Am Soc Nephrol 31: 1847–1858, 2020
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Vyas DA,
    2. Eisenstein LG,
    3. Jones DS
    : Medicine and society: Hidden in plain sight — reconsidering the use of race correction in clinical algorithms [published online ahead of print June 17, 2020]. N Engl J Med doi:10.1056/NEJMms2004740
  11. ↵
    1. Ferguson TW,
    2. Komenda P,
    3. Tangri N
    : Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens 24: 295–300, 2015 pmid:26066476
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 31 (8)
Journal of the American Society of Nephrology
Vol. 31, Issue 8
August 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Improving Equity in Medication Use through Better Kidney Function Measurement
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Improving Equity in Medication Use through Better Kidney Function Measurement
Delphine S. Tuot
JASN Aug 2020, 31 (8) 1657-1658; DOI: 10.1681/ASN.2020060880

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Improving Equity in Medication Use through Better Kidney Function Measurement
Delphine S. Tuot
JASN Aug 2020, 31 (8) 1657-1658; DOI: 10.1681/ASN.2020060880
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • Molecular Characterization of Membranous Nephropathy: Quo Vadis?
  • More than a Marker: Arginase-1 in Kidney Repair
  • Enabling Patient Choice: The “Deciding Not to Decide” Option for Older Adults Facing Dialysis Decisions
Show more Up Front Matters

Editorials

  • A Novel Pathological Mechanism of Tertiary Lymphoid Structure Formation in the Renal Pelvis
  • Disarming the Old Foe. Restoring T-Cell Immune Function with mTor-Inhibitors to Tackle Cytomegalovirus Infection
  • Genome-wide Admixture Mapping of eGFR and CKD Identify European and African Ancestry-of-Origin Loci in US Hispanics/Latinos
Show more Editorials

Cited By...

  • The Pathogenesis of Race and Ethnic Disparities: Targets for Achieving Health Equity
  • Google Scholar

Similar Articles

Related Articles

  • The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD
  • PubMed
  • Google Scholar

Keywords

  • disparities
  • diabetes
  • eGFR
  • metformin

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire